source
- Sanofi to pay $1 billion upfront to expand antibody partnership with RegeneronSanofi announced it will provide Regeneron with a $1 billion upfront payment to broaden their existing antibody collaboration. The agreement is timed as the patent protection for Dupixent, the joi…
- Sanofi pays Regeneron $1 billion upfront to co-develop four early-stage immunology assetsSanofi has agreed to pay Regeneron an upfront fee of $1 billion to partner on four early‑stage immunology programs, a move intended to capture the success of their joint Dupixent antibody. Dupixen…